RxDoctor Payments Data

Jonathan Matthews, DO

Internal Medicine · Trophy Club, TXNPI 1750432688

Payments from drug & device makers

$238in general payments, 2019–2025

Across 12 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$99
  • Novo Nordisk$43
  • AstraZeneca$36
  • Lilly USA, LLC$29
  • Dexcom, Inc.$16
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$15

What the payments were for

  • Food & beverage$238100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$238 in reported general payments places this provider in the 45th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$143,136
Medicare patients
159
Services billed
1,718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide158$185,918
EliquisApixaban74$70,619
MounjaroTirzepatide43$49,641
TrulicityDulaglutide16$27,689
RybelsusSemaglutide20$21,720
FarxigaDapagliflozin Propanediol11$20,967
LivaloPitavastatin Calcium13$11,615
XareltoRivaroxaban12$11,430
Breo ElliptaFluticasone/Vilanterol14$8,602
Humalog Kwikpen U-100Insulin Lispro16$7,623
EntrestoSacubitril/Valsartan11$7,614
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$6,597
LantusInsulin Glargine,hum.Rec.Anlog32$6,511
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen160$5,349
Testosterone Cypionate76$4,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$43$207,638178 claims
Lilly USA, LLCMounjaro, Trulicity$29$77,33159 claims
AstraZenecaFarxiga$36$20,96711 claims
AbbVieSynthroid$99$1,59926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Trophy Club

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →